Published in Hepatology on January 10, 2011
Management of opioid analgesic overdose. N Engl J Med (2012) 4.43
Molecular forms of HMGB1 and keratin-18 as mechanistic biomarkers for mode of cell death and prognosis during clinical acetaminophen hepatotoxicity. J Hepatol (2012) 3.15
Introduction to the revised American Association for the Study of Liver Diseases Position Paper on acute liver failure 2011. Hepatology (2012) 2.31
Intravenous N-acetylcysteine in pediatric patients with nonacetaminophen acute liver failure: a placebo-controlled clinical trial. Hepatology (2013) 1.78
Translational biomarkers of acetaminophen-induced acute liver injury. Arch Toxicol (2015) 1.49
RUCAM in Drug and Herb Induced Liver Injury: The Update. Int J Mol Sci (2015) 1.45
Protein-Derived Acetaminophen-Cysteine Can Be Detected After Repeated Supratherapeutic Ingestion of Acetaminophen in the Absence of Hepatotoxicity. J Med Toxicol (2015) 1.30
Acetaminophen-cysteine adducts during therapeutic dosing and following overdose. BMC Gastroenterol (2011) 1.26
Pathogenesis of idiosyncratic drug-induced liver injury and clinical perspectives. Gastroenterology (2013) 1.24
Acetaminophen protein adduct formation following low-dose acetaminophen exposure: comparison of immediate-release vs extended-release formulations. Eur J Clin Pharmacol (2012) 1.06
The UDP-glucuronosyltransferase (UGT) 1A polymorphism c.2042C>G (rs8330) is associated with increased human liver acetaminophen glucuronidation, increased UGT1A exon 5a/5b splice variant mRNA ratio, and decreased risk of unintentional acetaminophen-induced acute liver failure. J Pharmacol Exp Ther (2013) 1.05
Recent developments in acute liver failure. Best Pract Res Clin Gastroenterol (2012) 1.05
Drug-induced acute liver failure. Clin Liver Dis (2013) 1.03
Mechanisms of drug-induced liver injury. Clin Liver Dis (2013) 0.99
Targeted liquid chromatography-mass spectrometry analysis of serum acylcarnitines in acetaminophen toxicity in children. Biomark Med (2014) 0.93
Current and future directions in the treatment and prevention of drug-induced liver injury: a systematic review. Expert Rev Gastroenterol Hepatol (2015) 0.92
Advances in the management of acute liver failure. World J Gastroenterol (2013) 0.91
Confusion: acetaminophen dosing changes based on NO evidence in adults. Drugs R D (2012) 0.87
Prolonged Acetaminophen-Protein Adduct Elimination During Renal Failure, Lack of Adduct Removal by Hemodiafiltration, and Urinary Adduct Concentrations After Acetaminophen Overdose. J Med Toxicol (2015) 0.85
Candidate gene polymorphisms in patients with acetaminophen-induced acute liver failure. Drug Metab Dispos (2013) 0.85
The proper use of acetaminophen. Paediatr Child Health (2011) 0.82
The Honolulu Liver Disease Cluster at the Medical Center: Its Mysteries and Challenges. Int J Mol Sci (2016) 0.81
Acetaminophen Adducts Detected in Serum of Pediatric Patients With Acute Liver Failure. J Pediatr Gastroenterol Nutr (2015) 0.80
Comparison of Bile Acids and Acetaminophen Protein Adducts in Children and Adolescents with Acetaminophen Toxicity. PLoS One (2015) 0.80
Correlation of MRI findings to histology of acetaminophen toxicity in the mouse. Magn Reson Imaging (2011) 0.79
Liver: determining prognosis in acute liver failure. Nat Rev Gastroenterol Hepatol (2012) 0.79
Population prevalence of high dose paracetamol in dispensed paracetamol/opioid prescription combinations: an observational study. BMC Clin Pharmacol (2012) 0.79
Paracetamol (acetaminophen) protein adduct concentrations during therapeutic dosing. Br J Clin Pharmacol (2016) 0.78
The 100 most influential publications in paracetamol poisoning treatment: a bibliometric analysis of human studies. Springerplus (2016) 0.78
Association of Variants of Arginine Vasopressin and Arginine Vasopressin Receptor 1A With Severe Acetaminophen Liver Injury. Cell Mol Gastroenterol Hepatol (2017) 0.77
Determinants of outcome among patients with acute liver failure listed for liver transplantation in the United States. Liver Transpl (2016) 0.77
The role of hepatitis E virus infection in adult Americans with acute liver failure. Hepatology (2016) 0.75
Confirming the Causative Role of Acetaminophen in Indeterminate Acute Liver Failure Using Acetaminophen-Cysteine Adducts. J Med Toxicol (2015) 0.75
Detection of acetaminophen-cysteine adducts in cases of indeterminate liver failure is not diagnostic of intentional overdose. Hepatology (2011) 0.75
Drug Induced Liver Injury: Can Biomarkers Assist RUCAM in Causality Assessment? Int J Mol Sci (2017) 0.75
The Natural History of Severe Acute Liver Injury. Am J Gastroenterol (2017) 0.75
MicroRNA regulation of CYP 1A2, CYP3A4 and CYP2E1 expression in acetaminophen toxicity. Sci Rep (2017) 0.75
A model to predict survival in patients with end-stage liver disease. Hepatology (2001) 18.06
Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med (2002) 11.38
Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study. Hepatology (2005) 10.66
Early indicators of prognosis in fulminant hepatic failure. Gastroenterology (1989) 7.43
The management of fulminant hepatic failure. Prog Liver Dis (1970) 4.37
Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure. Gastroenterology (2009) 3.88
Measurement of serum acetaminophen-protein adducts in patients with acute liver failure. Gastroenterology (2006) 3.85
Detection of acetaminophen protein adducts in children with acute liver failure of indeterminate cause. Pediatrics (2006) 2.96
Acetaminophen poisoning and toxicity. Pediatrics (1975) 2.71
Determination of acetaminophen-protein adducts in mouse liver and serum and human serum after hepatotoxic doses of acetaminophen using high-performance liquid chromatography with electrochemical detection. Drug Metab Dispos (2002) 2.34
Intensive care of patients with acute liver failure: recommendations of the U.S. Acute Liver Failure Study Group. Crit Care Med (2007) 2.17
Pharmacokinetics of acetaminophen-protein adducts in adults with acetaminophen overdose and acute liver failure. Drug Metab Dispos (2009) 1.95
Acetaminophen-associated hepatic injury: evaluation of acetaminophen protein adducts in children and adolescents with acetaminophen overdose. Clin Pharmacol Ther (2008) 1.48
Immunochemical quantitation of 3-(cystein-S-yl)acetaminophen adducts in serum and liver proteins of acetaminophen-treated mice. J Pharmacol Exp Ther (1989) 1.28
Investigation of SEN virus infection in patients with cryptogenic acute liver failure, hepatitis-associated aplastic anemia, or acute and chronic non-A-E hepatitis. J Infect Dis (2003) 1.18
Brief report: no evidence for parvovirus B19 or hepatitis E virus as a cause of acute liver failure. Dig Dis Sci (2006) 1.16
Detection and diagnosis of herpes simplex virus infection in adults with acute liver failure. Liver Transpl (2008) 1.09
Immunoblot analysis of protein containing 3-(cystein-S-yl)acetaminophen adducts in serum and subcellular liver fractions from acetaminophen-treated mice. Toxicol Appl Pharmacol (1990) 0.98
Hepatitis B infection in patients with acute liver failure in the United States. Hepatology (2001) 0.93
Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med (2009) 14.31
Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med (2002) 11.38
Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study. Hepatology (2005) 10.66
Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med (2008) 9.33
Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster. Nat Genet (2006) 7.53
Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology (2008) 6.15
Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology (2010) 6.14
Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology (2002) 5.48
AASLD position paper: the management of acute liver failure. Hepatology (2005) 5.09
Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology (2009) 4.90
Viral and therapeutic control of IFN-beta promoter stimulator 1 during hepatitis C virus infection. Proc Natl Acad Sci U S A (2006) 4.84
Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology (2004) 4.27
Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure. Gastroenterology (2009) 3.88
Measurement of serum acetaminophen-protein adducts in patients with acute liver failure. Gastroenterology (2006) 3.85
Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C. Hepatology (2009) 3.50
Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. Control Clin Trials (2004) 3.46
Detection of hepatocellular carcinoma at advanced stages among patients in the HALT-C trial: where did surveillance fail? Am J Gastroenterol (2013) 3.41
Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology (2010) 3.35
Screening for Wilson disease in acute liver failure: a comparison of currently available diagnostic tests. Hepatology (2008) 3.04
Complication rate of percutaneous liver biopsies among persons with advanced chronic liver disease in the HALT-C trial. Clin Gastroenterol Hepatol (2010) 2.96
Detection of acetaminophen protein adducts in children with acute liver failure of indeterminate cause. Pediatrics (2006) 2.96
Autoimmune acute liver failure: proposed clinical and histological criteria. Hepatology (2011) 2.64
Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial. J Hepatol (2005) 2.63
Complications and use of intracranial pressure monitoring in patients with acute liver failure and severe encephalopathy. Liver Transpl (2005) 2.63
Mechanisms of acetaminophen-induced liver necrosis. Handb Exp Pharmacol (2010) 2.54
Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C. Gastroenterology (2010) 2.47
Herbal product use by persons enrolled in the hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial. Hepatology (2008) 2.44
Therapeutic hypothermia in acute liver failure: a multicenter retrospective cohort analysis. Liver Transpl (2015) 2.44
Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology (2004) 2.44
Determination of acetaminophen-protein adducts in mouse liver and serum and human serum after hepatotoxic doses of acetaminophen using high-performance liquid chromatography with electrochemical detection. Drug Metab Dispos (2002) 2.34
Introduction to the revised American Association for the Study of Liver Diseases Position Paper on acute liver failure 2011. Hepatology (2012) 2.31
Development of an accurate index for predicting outcomes of patients with acute liver failure. Gastroenterology (2012) 2.26
Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. Hepatology (2010) 2.26
Steroid use in acute liver failure. Hepatology (2013) 2.23
Intensive care of patients with acute liver failure: recommendations of the U.S. Acute Liver Failure Study Group. Crit Care Med (2007) 2.17
Incidence of minor complications and time lost from normal activities after screening or surveillance colonoscopy. Gastrointest Endosc (2006) 2.14
Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial. Hepatology (2006) 2.06
Hepatitis C virus treatment-related anemia is associated with higher sustained virologic response rate. Gastroenterology (2010) 2.06
Hepatitis C virus therapy update 2013. Curr Opin Gastroenterol (2013) 1.95
Pharmacokinetics of acetaminophen-protein adducts in adults with acetaminophen overdose and acute liver failure. Drug Metab Dispos (2009) 1.95
Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohort. Hepatology (2005) 1.93
Antimitochondrial antibodies in acute liver failure: implications for primary biliary cirrhosis. Hepatology (2007) 1.93
Minimal effects of acute liver injury/acute liver failure on hemostasis as assessed by thromboelastography. J Hepatol (2011) 1.85
Fulminant hepatitis A virus infection in the United States: Incidence, prognosis, and outcomes. Hepatology (2006) 1.83
Proteome and computational analyses reveal new insights into the mechanisms of hepatitis C virus-mediated liver disease posttransplantation. Hepatology (2012) 1.82
Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations. Hepatology (2013) 1.81
Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. Gastroenterology (2006) 1.76
Influence of high body mass index on outcome in acute liver failure. Clin Gastroenterol Hepatol (2006) 1.74
DNA polymorphisms and response to treatment in patients with chronic hepatitis C: results from the HALT-C trial. J Hepatol (2008) 1.71
Hepatic steatosis in hepatitis C: comparison of diabetic and nondiabetic patients in the hepatitis C antiviral long-term treatment against cirrhosis trial. Clin Gastroenterol Hepatol (2007) 1.71
Acetaminophen-induced hepatotoxicity: role of metabolic activation, reactive oxygen/nitrogen species, and mitochondrial permeability transition. Drug Metab Rev (2004) 1.65
Gc-globulin and prognosis in acute liver failure. Liver Transpl (2005) 1.59
Utilization of hepatocellular carcinoma surveillance among American patients: a systematic review. J Gen Intern Med (2012) 1.57
Predictive value of actin-free Gc-globulin in acute liver failure. Liver Transpl (2007) 1.55
Factors that determine the development and progression of gastroesophageal varices in patients with chronic hepatitis C. Gastroenterology (2010) 1.52
Infection and the progression of hepatic encephalopathy in acute liver failure. Gastroenterology (2003) 1.52
Outcomes and complications of intracranial pressure monitoring in acute liver failure: a retrospective cohort study. Crit Care Med (2014) 1.50
Translational biomarkers of acetaminophen-induced acute liver injury. Arch Toxicol (2015) 1.49
Failure rates in the hepatocellular carcinoma surveillance process. Cancer Prev Res (Phila) (2012) 1.49
Quantitative measurement of JWH-018 and JWH-073 metabolites excreted in human urine. Anal Chem (2011) 1.45
Cytochrome P450-mediated oxidative metabolism of abused synthetic cannabinoids found in K2/Spice: identification of novel cannabinoid receptor ligands. Drug Metab Dispos (2012) 1.41
Acetaminophen-induced hepatotoxicity in mice occurs with inhibition of activity and nitration of mitochondrial manganese superoxide dismutase. J Pharmacol Exp Ther (2010) 1.38
Marijuana-based drugs: innovative therapeutics or designer drugs of abuse? Mol Interv (2011) 1.38
Ischemic cholangiopathy following liver transplantation from donation after cardiac death donors. Liver Transpl (2008) 1.36
Predicting clinical and histologic outcomes based on standard laboratory tests in advanced chronic hepatitis C. Gastroenterology (2009) 1.35
A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C. Hepatology (2011) 1.33
Patterns of colonization in a metapopulation of grey seals. Nature (2002) 1.31
Keratin variants predispose to acute liver failure and adverse outcome: race and ethnic associations. Gastroenterology (2010) 1.28
Viral hepatitis-related acute liver failure. Am J Gastroenterol (2003) 1.28
Hepatitis B virus infection: current status. Am J Med (2005) 1.28
Recombinant plasma gelsolin infusion attenuates burn-induced pulmonary microvascular dysfunction. J Appl Physiol (1985) (2003) 1.28
Solid-phase extraction and quantitative measurement of omega and omega-1 metabolites of JWH-018 and JWH-073 in human urine. Anal Chem (2011) 1.27
Acetaminophen-cysteine adducts during therapeutic dosing and following overdose. BMC Gastroenterol (2011) 1.26
Population pharmacokinetics of metronidazole evaluated using scavenged samples from preterm infants. Antimicrob Agents Chemother (2012) 1.23
Evaluation of a new, rapid test for detecting HCV infection, suitable for use with blood or oral fluid. J Virol Methods (2010) 1.21
Limited contribution of common genetic variants to risk for liver injury due to a variety of drugs. Pharmacogenet Genomics (2012) 1.21
Investigation of SEN virus infection in patients with cryptogenic acute liver failure, hepatitis-associated aplastic anemia, or acute and chronic non-A-E hepatitis. J Infect Dis (2003) 1.18
Evolution of hepatic steatosis in patients with advanced hepatitis C: results from the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial. Hepatology (2009) 1.18
Proteomic profiling of human liver biopsies: hepatitis C virus-induced fibrosis and mitochondrial dysfunction. Hepatology (2007) 1.18
Differential dysfunction in dendritic cell subsets during chronic HCV infection. Clin Immunol (2007) 1.17
Efficacy and safety of entecavir in patients with chronic hepatitis B and advanced hepatic fibrosis or cirrhosis. Am J Gastroenterol (2008) 1.17
Brief report: no evidence for parvovirus B19 or hepatitis E virus as a cause of acute liver failure. Dig Dis Sci (2006) 1.16
Forensic investigation of K2, Spice, and "bath salt" commercial preparations: a three-year study of new designer drug products containing synthetic cannabinoid, stimulant, and hallucinogenic compounds. Forensic Sci Int (2013) 1.16